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Abbreviations  
ACK Ammonium-Chloride-Potassium 
ACE2 Angiotensin-converting enzyme 2 
ADCC Antibody-dependent cellular cytotoxicity 
APC Antigen-presenting cell 
ARDS Acute respiratory distress syndrome 
ARG1 Arginase 1 
CD Cluster differentiation  
CLP Common lymphoid progenitors  
CM/ TCM Central memory T cells 
CMP Common myeloid progenitors 
CMV Cytomegalovirus 
COVID-19 Coronavirus disease 2019 
CST Cytometer Set-Up and Tracking 
CTL Cytotoxic T lymphocytes  
CXCL1 Chemokine (C-X-C motif) ligand 1 
CyTOF Cytometry by Time-Of-Flight 
DAMPS Damage-associated molecular patterns 
DC Dendritic cell 
DMSO Dimethyl sulfoxide 
EDTA Ethylenediaminetetraacetic acid 
EFF Effector cell 
EM/TEM Effector memory T cells  
EMRA/ TEMRA Terminally differentiated effector memory T cells  
F/M Female/Male 
FACS Fluorescence-activated cell sorting  
FasL Fas ligand 
FC Flow cytometry 
FCS Fetal calf serum 
FlowSOM Self-Organising Maps  
fMLP N-formylmethionine-leucyl-phenylalanine 
FSC Forward scatter 
G-MDSC Granulocytic myeloid derived suppressor cell 
GMP Macrophage progenitors  
HIV Human immunodeficiency virus 
HLA Human leukocyte antigen 
HSC Hematopoietic stem cells 
HSV Herpes Simplex Virus  
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ICU Intensive care unit 
ITAM Tyrosine-based activation motif   
ITIM Immunoreceptor tyrosine-based inhibition motif 
IVD In-vitro diagnostic 
LN Lymph node 
LPS Lipopolysaccharides 
M-MDSC Monocytic myeloid derived suppressor cell 
MDSC Myeloid derived suppressor cell 
MEP Megakaryocyte and erythrocyte progenitors 
MFI Median fluorescence intensity  
MHC Major histocompatibility complex  
Min minutes 
MMP Matrix metalloproteinase 
MPO Myeloperoxidase 
NET Neutrophil extracellular traps  
NK cell Natural killer cell 
PAMPS Pathogen-associated molecular patterns 
PB Peripheral blood 
PBMC Peripheral blood mononuclear cell 
PBS Phosphate buffered saline solution 
PD-L1 Programmed death-ligand 1 
PMT  Photomultiplier tube 
PPR Pattern recognition receptors  
PROT-1 Proteomic stabiliser  
RBC Red blood cells 
ROS Reactive oxygen species 
rSD Robust standard deviation  
RT Room temperature 
RTE Recent thymic emigrant 
SARS-CoV-2 Severe acute respiratory syndrome-related coronavirus 2 
SCM Stem cell memory 
SLSS-V2 Stable-Lyse V2 and Stable-Store V2 
SSC Side scatter 
TCR T cell receptors 
UMAP Uniform Manifold Approximation and Projection  
wks weeks 
yrs Years 
γδ Gamma-delta  
Abstract Page 3 
Abstract 
Immunophenotyping by flow cytometry (FC) is an established practice to identify immune 
cells and their cellular changes at the single-cell level. Since preserving the structural integrity 
of cellular epitopes is vital for immunophenotyping, samples should be processed shortly 
after being collected.  However, the requirements of complex facilities and trained personnel 
for flow cytometry make it challenging to handle samples immediately. Fixation and 
cryopreservation extend sample shelf life and allow analysing longitudinal samples 
simultaneously while minimizing technical variation. Nevertheless, usage of whole blood 
cryopreservation in flow cytometry is limited due to challenges in preserving epitope 
structures during fixation and detecting dim antigens. 
This thesis investigates the performances of four commercial whole blood cryopreserving 
kits; 1) Cytodelics, 2) Stable-Lyse V2 and Stable-Store V2 (SLSS-V2), 3) Proteomic stabiliser 
(PROT-1), and 4) Transfix. Peripheral blood samples were processed with these stabilising 
buffers immediately after the collection and cryopreserved until further analysis by flow 
cytometry. Here, we measured the stability of major immune lineages, T cell subpopulations, 
and activated neutrophil profiles in samples treated with these commercial whole blood 
stabilisers.   
Our flow cytometry data showed that PROT-1, Transfix and Cytodelics maintained the 
distribution of major leukocyte subsets – granulocytes, T cells, natural killer cells and B cells, 
comparable to unpreserved samples despite the attenuation of fluorescence intensities. 
Moreover, these three stabilisers also preserved phenotypes of activated neutrophils upon 
stimulation with N-Formylmethionyl-leucyl-phenylalanine and Lipopolysaccharides. The 
upregulation of adhesion molecules (CD11b), Fc receptors (CD16) and granule proteins 
(CD66b) as well as the shedding of surface L-selectin (CD62L) on activated neutrophils was 
conserved most efficiently in PROT-1, followed by Cytodelics. On the other hand, none of the 
stabilisers provided a reliable detection of CCR7 for accurate quantification of T cell 
subpopulations.   
COVID-19 is caused by a highly transmissible and pathogenic coronavirus, so-called 
severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). To test the potential of whole 
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blood cryopreservation kits for flow cytometry in COVID-19 research, we studied the 
detectability of major leukocyte lineages and granulocyte subsets in longitudinal patient 
samples processed with Cytodelics. High dimensional analysis with Uniform Manifold 
Approximation and Projection (UMAP) and Self-Organising Maps (FlowSOM) clustering 
revealed remarkable stability of CD3, CD15, and CD14 expression in samples stored with 
Cytodelics.  It allowed the detection of lymphopenia and emergency granulopoiesis often 
found during the acute phase of severe SARS-COV-2 infection. Nonetheless, we could not 
determine signatures of granulocyte subsets, notably suppressive neutrophils, during the 
acute and convalescent phases of COVID-19. Variable detection of lowly expressed markers 
and diminished fluorescence intensities in Cytodelics - preserved samples might have 
hindered the analysis. 
In conclusion, this study demonstrates that PROT-1, Transfix, and Cytodelics enabled 
reliable detection of highly expressed leukocyte markers, whereas SLSS-V2 preservation 
resulted in the most inaccurate identification of studied markers. Notably, our results show 
that Cytodelics can be applied in COVID-19 studies to immunophenotype major immune 
lineages by flow cytometry.  Nevertheless, more optimisation is needed for less abundant or 
fixation-sensitive epitopes to enhance the efficacy of whole blood cryopreservation for flow 
cytometry. 
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1. Introduction 
1.1. Immunophenotyping    
1.1.1. Definition and methods 
Identifying immune cells and screening for their changes – so-called 
immunophenotyping, are fundamental in clinical and research work. With 
immunophenotyping, it is possible to measure the expression of both intracellular and surface 
antigens by labelling them with antibodies conjugated with signal molecules, ranging from 
fluorescent proteins in flow cytometry to rare metals in mass cytometry. Gene expression 
analysis is a more state-of-the-art method, providing a broader view of the immune 
landscape. However, high-cost and complex gene expression analysis and mass cytometry 
facilities make flow cytometry still more accessible and preferable in clinics and many 
laboratories. In addition, immunophenotyping by flow cytometry allows isolating specific cell 
populations for deeper transcriptomic studies1. Moreover, most biological samples such as 
blood, bone marrow, or tissues can be used for immunophenotyping, making the technique 
versatile for a wide range of clinical assessments and studies.2–4   
1.1.2. Application  
In clinical use, immunophenotyping allows physicians to detect and make an initial 
assessment of immune responses against diseases and evaluate the efficacy of the 
treatments. Routine immunophenotyping tests are commonly used in diagnosis and 
monitoring treatment and prognosis of cancers of hematopoietic origin, such as leukaemia, 
lymphoma, and myeloma. By simultaneously measuring multiple markers at the single-cell 
level, immunophenotyping by flow cytometry can enumerate and determine cell lineage, 
clonality, proliferation, or activation status of neoplastic cells. This information helps identify 
subgroups of blood cancer, evaluate patients’ responses to different treatments and monitor 
for the occurrence of minimal residual disease5. Information about enumeration and 
functional markers of several immune subsets also aids in diagnosing immunodeficiency 
diseases and uncharacteristic inflammatory symptoms6. 
Immunophenotyping is also the standard procedure in most of hepatology, 
immunology, and oncology research laboratories. It helps researchers characterise the 
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immune landscape of the studied materials and detailed information about expression 
patterns of several cellular proteins simultaneously. Moreover, immunophenotyping is a 
crucial part of clinical studies on immunotherapies to understand how much new treatments 
can boost or hinder immune responses and what the underlying mechanism might be.7,8 
1.2. Immune system 
1.2.1. Innate and adaptive immunity  
 
Figure 1: Overview of innate and adaptive immunity. Innate cells (green) recognise and phagocyte 
pathogens rapidly using pre-programmed receptors. Antigen-presenting cells such as dendritic cells 
then process and present pathogen antigens to T lymphocytes in lymph node (LN) and trigger adaptive 
immunity (yellow). As a result, activated T and B cells mount pathogen-specific attacks.  Reproduced 
with permission from reference.9 
 
Two major systems, innate and adaptive immunity, work closely together to fight off 
infection. Upon encountering microbes, pattern recognition receptors (PPRs) expressed by 
innate immune cells such as neutrophils or macrophages can recognise pathogen-associated 
molecular patterns (PAMPs) such as bacterial lipopolysaccharides (LPSs) and endotoxins. 
Upon binding to bacterial molecules, resident macrophages and neutrophils will phagocyte 
the bacterium and secrete proinflammatory cytokines and chemokines, triggering 
inflammation and attracting other immune cells. Local inflammation and phagocytosis of 
bacteria also activate complement system, a tightly regulated network of proteins. Upon 
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activation, complement system can opsonize, recruit phagocytes and trigger bacteria 
lysis.10,11 (Figure 1) 
After about seven days of infection, adaptive immunity is subsequently activated by 
antigen-presenting cells, such as dendritic cells (DC). After ingesting microbes, tissue-resident 
DCs migrate to lymph nodes and present pathogen antigens to T lymphocytes.  These DCs 
also provide co-stimulatory signals and cytokines needed to activate T cells. T cell activation 
results in clonal expansion and differentiation, generating effector cells and immunological 
memory specifically targeting pathogens of interest. Generated T cell subsets play a diverse 
function, e.g. activating B cells, destroying infected cells, enhancing phagocyte functions, 
worsening or resolving inflammation.12,13 (Figure 1)  
 
1.2.2. Major immune cells 
 
Figure 2: Major immune subsets. Hematopoietic stem cells (HSC) have the capacity of self-reviewing 
and differentiating into common myeloid progenitors (CMP) and common lymphoid progenitors (CLP). 
CMPs then differentiate into granulocyte and macrophage progenitors (GMP) and megakaryocyte and 
erythrocyte progenitors (MEP). These progenitors give rise to mature peripheral blood cells, as 
indicated at the bottom. RBC - red blood cell; NK - natural killer cells. The image was generated with 
Biorender.com and produced based on reference.14 
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Immune cells are the most active players of the immune system - our natural defence 
against pathogens or harmful physiological changes. They are originated from hematopoietic 
stem cells in the bone marrow. Depending on signal and timing, they can differentiate into 
common myeloid progenitors (CMP) and common lymphoid progenitors (CLP). The first 
subgroup develops into thrombocytes, red blood cells (RBC), and most innate immune cells 
such as eosinophil, neutrophil, basophils, and monocytes, each of which can possess a wide 
range of innate receptors to recognise and eliminate pathogens upon encountering. Except 
for natural killer cells and dendritic cells, most common lymphoid progenitors become either 
B cells (bone marrow-derived cells) and T cells (thymus cells), which require activation from 
innate immune system for effector functions and clonal expansion against pathogens as well 
as generating immunological memory (Figure 2).  
 
1.2.2.1. Monocytes 
Monocytes are the largest human leukocytes, making up only 2 to 10% of total 
circulating immune cells under normal conditions, but they are critical professional 
phagocytes and antigen-presenting cells. Monocytes are classified into three subgroups, 
namely classical, intermediate, and non-classical, depending on the expression of CD14 and 
CD16. The largest subgroup, classical monocytes defined as CD14++CD16-, are scavenger cells, 
removing bacterial pathogen and dying cells via phagocytosis. They can also activate or 
control other immune cells by producing proinflammatory cytokines. In addition, they can 
infiltrate tissues and differentiate into dendritic cells or sometimes macrophage15,16. On the 
other hand, intermediate and non-classical monocytes, defined as CD14+CD16+ and CD14-
CD16+ respectively, are more pro-inflammatory. Their primary functions are patrolling for 
injury, secreting a large number of proinflammatory cytokines, presenting antigens to T cells, 
and differentiating into antigen-presenting cells such as dendritic and macrophages.17   
In a clinical setting, measuring an absolute number of monocytes is part of routine 
blood tests. An elevated number of monocytes can indicate bacterial, viral, or parasitic 
infections, but also non-infectious diseases characterized by chronic inflammation such as 
inflammatory bowel syndrome, rheumatoid arthritis, or certain leukemia16,18. On the other 
hand, sepsis, aplastic anaemia or chemotherapy can cause monocytopenia, a condition with 
an abnormally low number of monocytes19,20.  
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1.2.2.2. Granulocytes 
The most abundant immune cells in circulation are granulocytes, which include 
neutrophils, basophils, and eosinophils. Cytoplasmic granules and segmented nuclei are the 
main features to characterise them. Upon infection, neutrophils and eosinophils can release 
cytotoxic granules, phagocyte pathogens and mediate inflammation. In comparison, 
basophils are more active in allergy.  
This study focuses on neutrophils since they account for up to 70% of circulating 
immune cells. There are about one billion neutrophils produced per kilogram of body weight 
each day, and this number can increase up to 10 billion cells during infection21. Developed in 
bone marrow, neutrophils are released into the circulation upon maturation. Without 
infection, their half-life is just about 6 to 8 hours22. Early signs of infection or inflammatory 
diseases can also be detected through the number of circulating neutrophils, which is 
routinely measured in a complete blood count.  
 
1.2.2.3. Neutrophil recruitment and activation  
 Neutrophils are recruited to infected sites by proinflammatory factors and 
chemotactic stimuli triggered by pathogen-associated molecular patterns (PAMPs) and 
damage-associated molecular patterns (DAMPs). These factors are, e.g. IL-8, IL-17, bacteria-
derived N-formylmethionine-leucyl-phenylalanine (fMLP), complement protein C5a, CXCL1, 
and CXCL2. Once released, they induce changes in surface proteins of the endothelium and 
subsequently lead to tethering and transmigration of the free-flowing neutrophils to the 
infected site.23  
In addition to host-derived stimuli and chemoattractants at the inflamed site, 
neutrophils can also be directly activated by PAMPs and DAMPs such as fLMP and LPS, which 
can bind directly to a repertoire of PPRs on neutrophils such as toll-like receptors, C-lectin like 
receptors, and NOD-like receptors. The binding triggers the MAPK/ERK signalling cascade, 
resulting in neutrophil effector functions such as oxidative burst and degranulation24. 
Neutrophil activation alters expression of cell surface receptors, such as upregulation of 
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integrin family (CD11b), Carcinoembryonic antigen-related cell adhesion molecule 8 (CD66b), 
complement receptor 1 (CD35), or downregulation of L-selectin (CD62L).25 (Figure 3) 
 
Figure 3: Overview of neutrophils recruitment, activation, and functions. Pathogen-associated 
molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs), and inflammatory 
cytokines make endothelial cells more permeable and trigger neutrophil recruitment and activation. 
Activated neutrophils then induce pathogen clearance by phagocytosis or production of reactive 
oxygen species (ROS) and neutrophil extracellular traps (NET), which can trap and limit the spread of 
the infection. In addition to that, released granules contain a diverse range of molecules such as 
myeloperoxidase (MPO) and matrix metalloproteinase (MMPs) to modulate inflammation. 
Neutrophils also play a necessary function in mediating adaptive immunity by interacting with T 
lymphocytes. fMLP, bacteria-derived N-formylmethionine-leucyl-phenylalanine; LPS, bacterial 
lipopolysaccharides. 
 
1.2.2.4. Neutrophil effector functions 
Upon activation, neutrophils play a diverse role in pathogen clearance, inflammation 
resolution, tissue damage, and autoimmunity. They are a complex and heterogeneous cell 
population, consisting of both pro-inflammatory and immunosuppressive subsets.  During the 
infection, degranulated neutrophils release proteolytic enzymes, antimicrobial peptides, or 
inflammatory molecules such as collagenases for neutrophil extravasation, myeloperoxidase 
for ROS production, or alpha-defensins directly targeting bacteria. Granule peptides such as 
cathelicidins can also participate in both antimicrobial and immunomodulatory activities.23,26  
In addition to degranulation, neutrophils can phagocyte pathogens opsonised by 
antibodies and induce oxidative burst, which causes damage directly to the pathogen, 
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enhance antiviral response and promote neutrophil extracellular traps (NET). These are web-
like chromatin structures embedded with neutrophilic granule proteins, capable of 
neutralising and destroying bacteria, fungi, or viruses.27,28  
Neutrophils are not solely efficient at eliminating microbial pathogens, but they also 
modulate other immune cell responses. For example, degranulating neutrophils can present 
antigens or release factors promoting T cell proliferation, whereas resting neutrophils can 
have immune-suppressive function depending on types of infection29.   Neutrophils can also 
act as antigen-presenting cells to memory CD4+ T cells and induce the production of 
antimicrobial antibodies.30,31, (Figure 3) 
 
1.2.2.5. Suppressive neutrophils  
Traditionally, suppressive neutrophils refer to myeloid-derived suppressor cells 
(MDSC). They are immature myeloid cells, which produce a high level of reactive oxygen 
species and arginase I to suppress T lymphocytes during pathological conditions such as 
cancer or infection32–34. Traditionally, human MDSCs are isolated from peripheral blood 
mononuclear cell (PBMC) fraction and subdivided into granulocyte-like MDSC (G-MDSC) 
described as Lin–HLA-DRlowCD11b+CD15+CD14– and monocytic MDSCs (M-MDSC) as Lin–HLA-
DRlow/–CD11b+CD33+CD14+33. However, despite attempts to define G-MDSC over the years, 
there is no good marker or consensus on how to distinguish them from other suppressive 
neutrophils yet.  
Since  Gabrilovich et al. proposed the term MDSC in 200732, different granulocyte 
subsets were found to have overlapping suppressive features of MDSC, such as mature low-
density neutrophils35,36.  Some studies suggested that G-MDSC is ‘a phenotype of 
neutrophils’37 or a subpopulation of degranulating granulocytes38. In other words, MDSCs or 
more specifically G-MDSCs can be considered as a heterogenous subgroup of suppressive 
neutrophils. They are increased especially during emergency myelopoiesis - a situation where 
immature and mature myeloid cells are generated rapidly in response to inflammation39. 
Thus, G-MDSC properties can manifest depending on the physiological cues regardless of 
their maturity.    
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1.2.2.6. Mechanism of immune suppression  
  
Figure 4: Mechanism of suppression by MDSCs and suppressive neutrophils. Arginase 1 (ARG1) and 
reactive oxygen species (ROS) can induce suppression by multiple pathways. G-MDSC, granulocytic 
myeloid derived suppressor cell. Reproduced with permission from reference.37  
 
G-MDSC and neutrophils can suppress T cell responses by releasing arginase-1 (ARG1) 
to interrupt T cell proliferation and activation. Arginase-1 released from the gelatinase-
containing granules depletes L-arginine in the microenvironment by converting them to l-
ornithine and urea37,40. In an L-arginine-derived microenvironment, T cell proliferation is 
arrested at G0-G1 phase41. ARG1 also mediates the attenuation of T cell activation by 
disrupting the recycling of TCR/CD3 complex and the reorganisation of actin cytoskeleton for 
immunological synapse formation42. Taken together, ARG1 can profoundly inhibit T cell 
function, and interestingly, overcoming arginine depletion has been shown to reconstitute T 
cell proliferation and boost immunotherapy in tumor microenvironment43,44(Figure 4).    
Production of reactive oxygen species (ROS) is another mechanism utilised by 
suppressive neutrophils or G-MDSCs. Like ARG1, oxidative stress interferes with the actin 
depolymerisation and recycling of TCR/CD3, thus blocking T cell function. A high level of ROS 
also induces T cell hypo-responsiveness by inhibiting NF-κB as well as triggering T cell 
apoptosis through Fas/FasL pathway45.  
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1.2.3. Lymphocytes  
1.2.3.1. Natural Killer cells  
A small portion of lymphoid progenitors differentiates into natural killer (NK) cells, an 
innate lymphocyte population. NK cell activation depends on activating and inhibitory 
receptors associated with immunoreceptor tyrosine-based activation motif (ITAM) and 
immunoreceptor tyrosine-based inhibition motif (ITIM), respectively. The activation occurs 
when the balance between inhibitory and activating signals is broken. In humans, they are 
subdivided into two main populations based on CD16 and CD56 expression - CD56dim and 
CD56bright. CD56dimCD16bright are considered cytotoxic ones since they mediate both natural 
and antibody-dependent cellular cytotoxicity (ADCC). The CD56bright CD16dim/- subgroup is 
regarded as a cytokine producer and the precursor of the CD56dim cytotoxic subset. NK cell 
deficiency can cause severe Cytomegalovirus (CMV) and Herpes Simplex Virus (HSV) 
infection.46–49 
 
1.2.3.2. B cells  
B cells, defined as CD19+, are the only cells that can produce antibodies and mediate 
humoral immunity. Naïve B cells harbour immunoglobulin receptors, mostly M and D type, 
which can bind diverse kinds of antigens, such as microbial proteins, lipids, polysaccharides, 
nucleic acids, and chemical toxins. B lymphocytes are activated upon antigen recognition and 
external signals, such as from T helper cells or complement system. Once activated, these 
cells undergo clonal expansion, giving rise to antibody-secreting plasma cells, high-affinity Ig 
expressing cells, or memory cells. After the first exposure with a protein antigen, long-lived 
plasma cells and memory cells return to the bone marrow and stay dormant there for a long 
time. These cells ensure more rapid and efficient responses in the subsequent exposure by 
producing a more significant number of antibodies and faster affinity maturation of the 
antibodies produced.  Activated B cells can also undergo isotype switching, generating 
different types of antibodies with the same specificity, resulting in more effective immune 
responses against certain pathogens.50,51 
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1.2.3.3. T cells  
Originated from bone marrow, thymus-seeding progenitor cells migrate to thymus to 
mature and differentiate into thymocytes that will eventually become mature T cells. Central 
event in the maturation of thymocytes is the gene rearrangement to generate T cell receptors 
(TCR).  After the TCR rearrangement, T cells must pass negative and positive selection, 
meaning that they can tolerate self-structures and have sufficient affinity for self-major 
histocompatibility complex (MHC) or human leukocyte antigen (HLA) in humans. Two 
dominant lineages that emerge from thymus are categorized based on their co-receptors 
expressed as CD4 – T helper cells, and CD8 – cytotoxic cells.12 
 
1.2.3.3.1. CD4 and CD8 T cells 
CD4 T helper cells are actively involved in the regulation of both innate and adaptive 
responses. Depending on the type of activation and cytokine signalling they receive, CD4 T 
cells can differentiate into distinct subsets. Each subset subsequently activates or modulates 
activities of specific immune cells, depending on types of pathogens. Also, CD4 cells exhibit 
both pro-inflammatory and immunosuppressive functions.52,53 
CD8 cells – cytotoxic T lymphocytes (CTL) are the prominent “foot soldiers of the 
immune system”54. Upon engaging with MHC-Class I bearing known pathogenic antigens, CD8 
cells rapidly destroy infected cells by releasing cytotoxic granules containing perforins and 
granzymes. Subsequently, the caspase cascade will be activated in the infected cells, resulting 
in cell death. CTLs can also induce cell death through the Fas-FasL pathway, particularly to 
maintain immune homeostasis.12,55,56  
Classical T cells egress from the thymus as naïve cells and enter circulation. Among 
naïve cells, recent thymic emigrants (RTEs) are the youngest T cells, which are the most recent 
cells entering the lymphoid periphery. RTEs are an indicator of thymic output and a critical 
parameter maintaining the peripheral pool of diverse T cells. Their capacity of proliferation 
and cytokine production is lower compared to mature naïve cells. In human, platelet 
endothelial cell adhesion molecule known as CD31 is used to identify RTEs. Understanding 
RTEs and thymic output is essential in monitoring immunodeficiencies or immune-
reconstitution after hematopoietic stem cell transplantation.57–59 
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Figure 5: Different subsets of circulating T cells. Each subgroup has a different capacity of 
differentiation and proliferation. CD62L and CCR7 are the primary receptors for trafficking to 
secondary lymphoid tissues. SCM, stem cell memory; CM, central memory; EM, effector memory; EFF, 
effector; APC, antigen-presenting cell. Reproduced with permission from reference52.  
 
Mature naïve T cells migrate to secondary lymphoid tissues. There, they can be 
activated only after receiving all three distinct signals: (1) recognition of antigen-HLA complex, 
(2) specific antigen co-stimulation and (3) appropriate cytokines for activation and 
proliferation60. Upon activation, T cells will proliferate and differentiate into effector and 
memory cells bearing the same antigen specificity. After re-entering the circulation, the 
effector cells migrate to the infected area to clear out infection while the memory cells survey 
lymphatic tissues for the same pathogenic antigen.12 
  There are three main subsets of memory cells, depending on expression of CD45RO, 
CD45RA, and CCR7 (Figure 5).  Effector memory (TEM) can enter the infected site by expressing 
different integrins and chemokine receptors such as CCR5. They are active in the immediate 
adaptive response by producing a large number of effector cytokines and perforin61. On the 
other hand, the central memory cells (TCM) express peripheral homing receptors such as CCR7 
and CD62, making them more restricted to secondary lymphoid tissues. While providing 
primary immunosurveillance of known pathogens, TCM cells can rapidly proliferate and give 
rise to both effector and TEM cells.  Another subset of memory, so-called terminally 
differentiated effector memory cells (TEMRA), re-expresses CD45RA. It is not clear about the 
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functions of TEMRA cells, which express markers for senescence and have low functional and 
proliferative capacity. Figure 5 gives a summary of these subsets and their corresponding 
surface markers.52,61  
 
1.2.3.3.2. Gamma delta T cells 
 Gamma-delta (γδ) T cells, characterised by their unique expression of γδ TCR, are non-
conventional cells, accounting for less than 5% of total circulating lymphocytes. Nonetheless, 
they are more abundant in peripheral tissues such as the skin and gut mucosa. In addition, γδ 
T cells resemble conventional alpha-beta (αβ) T cells regarding their cytotoxic activities and 
cytokine production. However, unlike αβ cells, γδ T lymphocytes’ functional responses are 
independent of MHC molecules and antigen-presenting cells.62 
γδ T cells can recognize a wide range of pathogenic and stress antigens and display NK-
like effector functions. Moreover, they are capable of processing antigens and cross-
presenting them to conventional T cells and other immune cells. In addition to immune 
surveillance of infection and tumor microenvironment, γδ T cells also contribute to the 
homeostasis of tissue physiology and control neuronal synaptic plasticity in the central 
nervous system. Aberrant activities of γδ T were found in autoimmune diseases (e.g. systemic 
sclerosis) and infection such as human immunodeficiency virus (HIV) infection. Thus, 
phenotyping γδ T cells is essential given their diverse subsets and functions.62–64 
 
1.3. Immune responses during SARS-COV-2 infection 
As of September 2021, SARS-CoV-2, a pathogenic coronavirus, has claimed more than 
4.5 million lives globally since it emerged in 2019 in Wuhan, China. Being a single-stranded 
RNA virus, SARS-CoV-2 can cause a wide range of clinical manifestations, depending on an 
individual’s age and co-morbidities. While young and healthy people most often experience 
mild to moderate disease, some with pre-existing medical conditions and impaired immune 
system can develop severe respiratory illness, many of whom have succumbed to death.65–67 
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1.3.1. Immunopathogenesis  
To enter host cells, the spike protein of SARS-CoV-2 binds to angiotensin-converting 
enzyme 2 (ACE2) that is abundantly expressed on airway epithelial cells68. Host TMPRSS2 
enzyme then cleaves the spike protein, allowing the viral membrane to fuse with the host 
cells69. At the end of its replicating cycle, SARS-CoV-2 induces death and injury in the infected 
host cells, a majority of which are lung epithelial cells. SARS-CoV-2 is linked to pyroptosis, a 
highly inflammatory form of cell death, which results in proinflammatory cytokine secretion70. 
In healthy individuals, this is a signal for the recruitment of immune cells, such as T 
lymphocytes, to clear out the infection and resolve the inflammation. However, an impaired 
immune system might lead to a massive level of cytokines released and unrestrained immune 
cell infiltration to the lungs, which might be a reason for the lymphopenia often seen in 
COVID-19 patients. These infiltrated cells produce an excessive amount of reactive oxygen 
species and proteases that mediate the lung damage further66. In addition, SARS-CoV-2 viral 
proteins can antagonise the host interferon responses, helping the virus escape innate 
immunity71. Taken together, it is crucial to understand the host responses since the severity 
of SARS-CoV-2 is not only from the viral infection itself but also from the dysfunctional 
immune reaction.  
 
1.3.2. Neutrophils and challenges of studying them in the context of COVID-19 
Accounting for up to 70% of the total circulating immune cells, neutrophils play an 
active role in both resolving and worsening the SARS-CoV-2 infection. Increased neutrophil to 
lymphocyte ratio is an indicator of a poor outcome in COVID-1972. There is an increase in both 
circulating and lung-infiltrated neutrophils. Their activation and degranulation markers are 
also increased73.  Notably, severe cases displayed an expansion of immature and low-density 
neutrophils. Many of these cells are suppressive and can dampen the adaptive immune cell 
responses72. Together with activated neutrophils, these cells also release a high level of NETs, 
triggering immunothrombosis and possibly mediating acute respiratory distress syndrome 
(ARDS)74. There are still many remaining questions about the driving forces of aberrant 
neutrophil responses, NETs formation, and clearance during the SARS-CoV-2 infection.  
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To answer those questions, collecting high-quality samples is the first step. Since 
neutrophils are short-lived, easily activated upon blood drawing, and very sensitive to cryo-
preservation, it is crucial to have a reliable method to stabilise samples immediately after 
being taken. Fresh blood samples or PBMC fractions are often used in neutrophil studies so 
far. Though they allow investigating neutrophil heterogeneity in depth, PBMC isolation 
process can alter neutrophil characteristics. On the other hand, processing fresh samples 
individually is demanding due to logistic and technical requirements, particularly during the 
pandemic.73,75,76 
In addition, COVID-19 sample processing is challenging because SARS-CoV-2 is highly 
transmissible through droplets, aerosols, and fomites77. In other words, there is a need for a 
method that ensures both sample quality and staff safety.  Here, we aimed to study whether 
commercially available whole blood stabilisers are suitable to study neutrophils with flow 
cytometry, which is the most popular immunophenotyping method globally.  
 
1.4. Cryopreservation 
Cryopreservation uses sub-zero temperatures to preserve the integrity and even 
viability of organelles, cells, tissues, or organs over a long period. Depending on types of 
samples and nature of research projects, cryogenic temperatures can range from –4°C to –
140°C. At these temperatures, most of the biological activities are either reduced or stopped, 
preventing further changes or destruction of cellular structures. These features are critical to 
maintain intact cellular characteristics after removing cells from their physiological 
environment. Because of this, the method is widely used in clinics and research. Moreover, 
cryopreservation allows a considerable number of patient samples to be collected 
prospectively and analysed simultaneously to reduce technical variation and batch effects.78  
Despite being widely used and optimised, cryopreservation of human samples 
efficiently is still challenging. During the freezing process, ice crystal formation and osmotic 
shock can damage cellular membranes, thus reducing samples’ viability and quality. To 
minimise these cryo-damages, cryoprotectants such as Dimethyl sulfoxide (DMSO) and 
glycerol are often added to the freezing media. In addition to that, freezing containers with a 
Introduction Page 19 
cooling rate of –1°C per minute can be used to reduce cellular damage due to temperature 
shock.78 
Compared to other immune cells, granulocytes are particularly sensitive to the 
freezing process, and thus they are recommended to be analyzed within 2-4 hours of 
collection79. Clinical samples are often collected in hospitals and transferred to a separate 
flow cytometry unit for processing. Due to the logistics, analysing clinical samples within the 
recommended time frame of 4 hours is not always possible. Moreover, variation in sampling 
dates, handling personnel, and delaying time between sample collection and analysis can 
generate batch effects. 
Moreover, sample processing can disrupt both chemical and mechanical homeostasis 
of granulocytes. Upon sensing those stimuli, neutrophils can switch between their activation 
or deactivation status80. Therefore, minimal intervention and gentle treatment are needed to 
preserve neutrophil properties. Cryoprotectants such as glycerol, osmotic stress, and cold 
shock during cryopreservation can significantly damage the neutrophils, resulting in the loss 
of functions and low viability81,82. Though limited to immunophenotyping only, fixation prior 
to cryopreservation of whole blood might retain neutrophil properties better than multi-step 
procedures. 
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2. Aims and hypothesis 
This thesis project aims to compare the performance of different whole blood 
cryopreservation for immunophenotyping by flow cytometry using stabilising reagents 
commercialised primarily for mass cytometry – Cytodelics (Cytodelics AB, Stockholm, 
Sweden), Stable-Lyse V2 and Stable-Store V2 (SLSS-V2), and Proteomic stabiliser (PROT-1) 
(Smart Tube Inc., San Carlos, CA, US). As flow cytometry and mass cytometry both measure 
physical and chemical properties of single cells using antibodies, we hypothesised that these 
cryopreserving reagents should maintain cellular characteristics comparable to fresh samples 
and sufficient for measurements in flow cytometry.  
Our objectives are as follows:  
1. Determine the suitability of Cytodelics, SLSS, and PROT-1 for preserving general 
surface markers of different cell lineages – lymphocytes, monocytes, and granulocytes,  
2. Study variables that might affect the sample quality before and after freezing, such 
as variations in sample processing, antibody clones and experimental workflow.  
3. Evaluate the effects of stabilising reagents on neutrophils and their activation 
markers,  
4. Assessing the feasibility of using Cytodelics for a longitudinal analysis of COVID-19 
immune responses.   
5. Explore how different subsets of neutrophils, specifically suppressive subtype 
including myeloid-derived suppressor cells (MDSC), change throughout the disease and how 
these changes might be associated with the outcome of COVID-19.  
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3. Materials and Methods 
3.1.  Clinical samples  and patient characteristics 
3.1.1. For whole blood cryopreservation study  
Peripheral blood (PB) samples were collected by venepuncture to BD Vacutainer® 
EDTA tubes. Within 3 hours after the venesections, samples were added to cryo-tubes 
containing whole blood stabilising reagents and further processed according to 
manufacturers’ recommendations. 
 
3.1.2. For longitudinal study in COVID-19 
Table 1: COVID-19 patient characteristics 
Characteristic Hospitalised ICU 
Characteristics   
Total number  8 7 
Age (yrs) 59 [34 - 65] 58 [46 - 69] 
Gender (F/M) 6 (86%) / 1 (14%) 3 (43%) / 4 (57%) 
Hospitalisation days 6 [4 - 15] 15 [10-38] 
Comorbidities    
Asthma (n) 4 (57%) 1 (14%) 
Hypertension (n) 1 (14%) 1 (14%) 
Obesity (n) 1 (14%) 4 (57%) 
Cardiovascular disease (n) NA 2 (29%) 
Obstructive sleep apnea (n) 1 (14%) 2 (29%) 
Diabetes (n) NA 2 (29%) 
Data are reported as median with range or number (%). ICU, intensive care unit. F/M, 
Female/male.  
 
Patients hospitalized due to COVID-19 at the Helsinki University Hospital, Helsinki, 
Finland were invited to participate in the study. Inclusion criteria were SARS-CoV-2 infection 
confirmed by polymerase chain reaction test. However, patients undergoing 
immunosuppression treatment (e.g. Dexamethasone) were excluded from the study. PB 
samples were collected by venepuncture to BD Vacutainer® EDTA/ heparin blood collection 
tubes. 0.5ml PB samples were incubated with 0.5ml Cytodelics’s stabiliser at RT for 10 minutes 
and then stored at -80°C. 
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All clinical samples were subgrouped based on severity. Hospitalised samples 
indicated milder cases, whereas subjects admitted to intensive care unit (ICU)  were 
considered severe cases. Sampling taken within 15 days from symptom onset was categorised 
as the acute, whereas samples taken after 90 days were assigned to the convalescent group. 
However, three samples of the hospitalised cohort which were taken less than 90 days 
(specifically after 22, 61 and 77 days from symptom onsets) were included in the analysis as 
convalescent samples. Table 1 summarizes the characteristics of patient samples. 
 
3.2. Ethical statement  
The study was approved by the Ethics Committee of the Hospital District of Helsinki 
and Uusimaa (HUS/853/2020 and HUS/747/2019). All samples were taken with informed 
consent.  
3.3. FACS Lysis solution  
Fresh blood samples were stained with fluorochrome-conjugated antibodies for 25 
minutes at RT and subsequently subjected to 1X BD Facs Lysing in 10 minutes at RT. Cells were 
washed twice with FACS staining buffer (2% FCS + 2mM EDTA in PBS) before being acquired 
on the flow cytometer  
3.4. Whole blood cryo-preservation and thawing  
Table 2: Overview of four commercial whole blood cryopreservation kits with BD Facs Lysing 
solution used as a fresh control 
  
BD Facs Lysing 
(Fresh & unpreserved)   
Cytodelics PROT-1 SLSS-V2 Transfix 
Erythrocyte lysis  yes yes yes yes yes 
Formaldehyde fixation 10% < 5 % 3-7% unknown <1% 
Methanol 
permeabilisation 
3.50% unknown unknown unknown unknown 




Freezing time (min) - 10 10 30 15 
Preserving temperature  - -20 or -80 -80 RT/+4/-80°C +4°C 
Storage duration  - 1 yrs 13 months83  
>2wks at +4°C 
unknown at -80°C 
14 days 
Thawing/RBC lysing (min) - 30 ～50 ～10 ～15 
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3.4.1. Cytodelics (Cytodelics AB, Sweden)  
Stabilisers were calibrated at RT for 5 minutes before mixing with the blood. The 
samples were kept at RT for 10 minutes before being stored at -80°C until analysis. Upon 
analysis, these samples were quickly thawed at +37°C for 2 minutes, followed by a 15-minute 
incubation with fixing solution (Cytodelics AB) at RT. RBCs were then lysed in lysing buffer 
(Cytodelics AB) for 15 minutes at RT.  The supernatant was removed by centrifugation at 300g 
for 10 minutes at RT. Cells were washed twice with wash buffer (Cytodelics AB) and flow 
cytometry staining buffer subsequently.  
 
3.4.2. Proteomic stabilisers (Smart tubes, CA, US) 
Blood samples were incubated in proteomic stabiliser (PROT1) solution for 10 minutes 
at RT and transferred to a -80°C freezer for storage. Samples were thawed in a +10°C water 
bath. RBCs were lysed by incubating samples in 1x thaw-lyse buffer (Smart tubes Inc) for 10 
minutes at RT.  Cells were collected after centrifugation at 600g for 5 minutes at RT. RBC lysis 
was repeated one more time before processing to staining.  
 
3.4.3. Stable lyse – stable store V2 reagent (Smart tubes, CA, US) 
Blood samples were added to Stable Lyse solution (Smart tubes Inc) and incubated at 
RT for 15 minutes. Subsequently, Stable Store solution (Smart tubes Inc) was added, and the 
samples were kept at RT for another 15 minutes before being stored at -80°C. Upon analysis, 
samples were thawed in a +10°C water bath and washed twice with staining buffer before 
staining.  
 
3.4.4. Bulk Transfix (Cytomark, UK)  
0.1ml bulk transfix solution was added to 0.5ml of blood samples, followed by a 15-
minute incubation at RT. Samples were kept at +4°C for a maximum of 2 weeks before 
analysis. Before using, samples were kept at RT for 15 minutes. The cells were resuspended 
thoroughly and transferred to FACS tubes before continuing with a stain-lyse-wash 
procedure. After fluorochrome-conjugated monoclonal antibody mixture was added, 
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samples were incubated in dark at RT for 25 minutes. Afterwards, samples were subjected to 
1x BD FACS™ lysing solution (BD Biosciences),  
 
3.4.5. Peripheral Blood Mononuclear Cell Isolation and freezing 
Blood was diluted with phosphate buffered saline solution (PBS) (1:3) before being 
layered on top of Ficoll® Paque Plus (GE Healthcare, USA). The ratio of blood to Ficoll followed 
the manufacturer’s recommendation. Samples were then centrifuged at 400g for 30 minutes 
at RT without break. After the centrifugation, PBMCs were collected from the cloudy layer 
above Ficoll, followed by two washes with PBS.  
In a cryotube, 500ul CTL-Cryo™ C Media (ImmunoSpot, USA) was added to 5-10 million 
PBMCs. CTL-Cryo™ AB Media was mixed before using and kept at 37oC. CTL-Cryo™ AB is added 
to the cryotube containing PBMC by dropwise over 2 minutes on a low-speed vortex. The 
mixture was immediately placed into Mr Frosty™ Freezing Container (Thermo ScientificTM, 
USA) or a CoolCell controlled-rate freezing container (BioCision, USA) and moved to -80°C 
freezers  
Upon thawing, samples were placed in a +37oC water bath for 2 minutes. All medium 
from each cryovial was transferred to a 50ml conical tube. To yield high cell viability, the first 
3ml of thawing media (90% RPMI, 10% CTL wash, 10ug/ml DNase) was added slowly while 
gently swirling the tube, followed by adding another 7ml of thawing media at an average 
speed. Samples were centrifuged at 330g for 10 minutes, and the supernatant was removed. 
The process was repeated twice to remove all DMSO and preservative reagents.  
 
3.5. Granulocyte activation 
Whole blood was stimulated with 5ug/ml LPS or 100umol/ml for 1 hour in a +37°C 
incubator with 5% CO2. The reaction was stopped and washed with cold PBS. Cells were then 
centrifuged at 330g for 10 minutes. The cell pellet was reconstituted in PBS and processed 
further with either BD FACS lysing for immediate analysis or stored in different 
cryopreservation reagents for later use.   
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3.6. Flow cytometry  
3.6.1. Panel design  
First, populations of interest were defined. The expression density of each marker and 
co-expression were then assessed.  The information was combined with data from a 
resolution impact matrix to minimise spectral spillover and loss of resolution. In general, dim 
fluorochromes were assigned to well-defined and highly expressed proteins and vice versa. 
Two co-expressed proteins were put into no or very few overlapping channels. How these 
conditions were addressed was also dependent on flow cytometers and the availability of 
antibodies. However, the resolution of target populations was maximised to the best extent. 
The designing process was aided by BD Horizon™ Guided Panel Solution tool84.  
 
3.6.2. Compensation  
Compensation was used to correct for the fluorescence spillover. Compensation 
matrices were established from single staining files using CompBead Ig, κ/Negative Control 
Particles Set (BD Biosciences).  Used antibodies were similar to corresponding panels (Table 
3Table 3: Fluorescence–labelled antibodies used in each panel). To ensure the accurate 
positive signal of dim populations, photomultiplier tube (PMT) voltage of each channel was 
set so that the robust standard deviation (rSD) of the negative population was placed at 
2.5xrSD of the electronic noise. Later, compensation matrices were generated automatically 
in Flowjo software and applied to the acquired flow cytometric data  
 
3.6.3. Staining and acquisition  
Prior to the staining, all antibodies were titrated using Cytodelics-preserved samples. 
The final antibody concentration was selected based on the highest separation index85. 
Separation Index =
MedianPositive −  MedianNegative
(84%Negative −  MedianNegative)/0.995
 
Monitoring of flow cytometer performance was performed at each cold start. The 
instrument was left on for 20 to 30 minutes to warm up and standardize lasers. Then 
Cytometer Set-Up and Tracking (CST) beads (BD Biosciences, USA) was run to track the 
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instrument performance and any deviation from the baseline. Samples were acquired only 
when all parameters passed the CST test.  
All staining was done in dark at +4°C. One to five million cells were first suspended in 
Brilliant Stain Buffer (BD Bioscience, USA). In some experiments, samples were first treated 
with 2.5μg Human BD Fc BlockTM (BD Biosciences) or 100U/ml Heparin (Sigma-Aldrich, USA) 
for 20 minutes. Subsequently, an antibody cocktail for surface markers was added, followed 
by a 30-minute incubation. If needed, the samples were then washed with 1X 
permeabilisation buffer (eBioscience, USA), followed by staining with antibodies for 
intracellular markers for 30 minutes in dark at 4°C. After washing twice with FACS staining 
buffer (PBS with 2% FCS and 2mM EDTA), they were ready for acquisition in LSRII Fortessa 
(BD Biosciences, USA). About 120 000 to 250 000 cells were recorded for studying the whole 
blood stabilisers, and about 1 to 1.5 million cells were recorded for the COVID-19 
experiments.  
Table 3: Fluorescence–labelled antibodies used in each panel 
Fluorochrome Antigen Clone Host Cat number Manufacturer 
Panel for immune cell lineages 
PE HLA-DR MEM-12 Mouse 21278994 ImmunoTools 
PE-CF594 CD8 RPA-T8 Mouse 562282 BD Biosciences 
PerCP-Cy5.5  CD14 M5E2 Mouse 550787 BD Biosciences 
APC CD3 HIT3b Mouse 21810036 ImmunoTools 
APC-R700 CD56 NCAM16.2 Mouse 565140 BD Biosciences 
APC-H7 CD45 2D1 Mouse 560274 BD Biosciences 
BV421 CD4 RPA-T4 Mouse 562424 BD Biosciences 
BV510 CD15 W6D3 Mouse 563141 BD Biosciences 
BV605 CD19 HIB19 Mouse 302244 BioLegend 
BV786 CD16 3G8 Mouse 563690 BD Biosciences 
Panel for granulocyte activation 
FITC CD19 HI19a Mouse 21810193 ImmunoTools 
FITC CD56 MEM-188 Mouse 21270563 ImmunoTools 
FITC CD14 18D11 Mouse 21620143 ImmunoTools 
FITC CD3 HIT3b Mouse 21810033 ImmunoTools 
PE-Cy7 CD66b G10F5  Mouse 25066642  Invitrogen  
Per-CP cy5.5 CD69 FN50 Mouse 560738 BD Biosciences 
APC siglec8 7C9 Mouse 347105 biolegend  
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Fluorochrome Antigen Clone Host Cat number Manufacturer 
AF780 CD62L DREG-56  Mouse 47-0629-42  eBioscience  
BV421 CD45 HI30 Mouse 563880 BD Biosciences 
BV510 CD15 W6D3 Mouse 563141 BD Biosciences 
BV605 Cd11b ICRF44  Mouse 562723 BD Biosciences 
BV786 CD16 3G8 Mouse 563690 BD Biosciences 
Panel for T lymphocytes 
FITC CD19 HI19a Mouse 21810193 Immunotools 
FITC CD14 18D11 Mouse 21620143 Immunotools 
PE-CF594 CCR7 (CD197) 150503 Mouse 562381 BD Biosciences 
Pe-Cy7 CD31 WM59  Mouse 563651  BD Biosciences 
Alexa Fluor 700 CD3 UCHT1  Mouse 557943  BD Biosciences 
BV421 CD95 (FAS) DX2  Mouse 562616  BD Biosciences 
BV510 CD4 SK3  Mouse 562970  BD Biosciences 
BV605 TCRgd B1  Mouse 740415  BD Biosciences 
BV650 CD8 SK1  Mouse 344730  Biolegend  
BV711 CD45RA HI100  Mouse 563733  BD Biosciences 
Panel for Neutrophils in COVID-19 
FITC CD19 HI19a Mouse 21810193 ImmunoTools 
PE CD33 WM53 Mouse 555450 BD Biosciences 
PE-Cy7 Ki-67 B56 Mouse 561283 BD Biosciences 
Per-CP cy5.5 HLA-DR L243 Mouse 552764 BD Biosciences 
APC ARG1 14D2C43 Mouse 369706 Biolegend  
Alexa Flour 700 CD3 UCHT1 Mouse 557943 BD Biosciences 
APC-Cy7 CD11b M1/70 Rat 101226 Biolegend  
BV421 Lox-1 NA Mouse 358610 Biolegend  
BV510 CD15 W6D3 Mouse 563141 BD Biosciences 
BV605 CD16 3G8 Mouse 563173 BD Biosciences 
BV711 CD274 (B7-H1) 29E.2A3 Mouse 329721 Biolegend  
BV786 CD14 M5E2 Mouse 563698 BD Biosciences 
 
3.7. Analysis  
The obtained flow cytometry data were analysed with Flowjo software (v10.7.1, BD 
Bioscience, USA). The sample median values in matched materials were compared by 
statistical tests for non-parametric data as indicated in each figure. The statistical analysis and 
graph design were performed using Prism 9 (GraphPad Software Inc, USA).  A P-value smaller 
than 0.05 was considered statistically significant.  
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High-dimensional data analysis of flow cytometry data 
Uniform Manifold Approximation and Projection (UMAP) and Self-Organising Maps 
(FlowSOM) clustering was performed on the Flowjo software. All FCS files were preprocessed 
to correct for spectral spillover and remove debris, singlets, eosinophils and B cells. An equal 
sampling of 10000 events from each FCS file was done using DownSample plugin in Flowjo, 
which were then concatenated into a single flow cytometry file of 280 000 cells. The following 
markers were used for FlowSOM and UMAP analysis: CD3, CD15, CD16, CD14, HLA-DR, 
CD11b, CD33, CD274 (PD-L1), ARG1, LOX-1, Ki-67. All cells were projected on UMAP’s two-
dimensional space. UMAP plots were generated with Euclidean distance, 10 for nearest 
neighbor, 0.5 for minimum distance and 2 for total components. Resulting UMAP plots were 
fed into the FlowSOM clustering algorithm (number of cluster=13)86. 
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4. Results  
4.1. Optimisation of whole blood stabilisers  
 
Figure 6: Overview of stabiliser effects. (A) Representative FSC/SSC profile of the same donor resulted 
from each stabiliser. (1) Eosinophils; (2) Neutrophils; (3) Monocytes; (4) Lymphocytes. Note that FSC 
files of each stabiliser were recorded at different FSC/SSC voltages to capture all the events. (B)(C) 
Effects of clones, FcR block, and 100U/ml heparin on CD16 staining of samples preserved in Cytodelics 
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Samples treated with BD FACS Lysing solution were considered as fresh and 
unpreserved control in our study. A stain-lyse-wash procedure was used to minimize the 
effects of fixation and permeabilization on antibody staining. Our preliminary data showed 
that BD FACS Lysing Solution lysed RBCs and maintained distribution of major immune sup-
population equivalent to samples traditionally processed with Ammonium-Chloride-
Potassium (ACK) lysis buffer (data not shown). Furthermore, according to Euroflow 
standardization published on Nature Leukemia, BD FACS Lysing solution also yielded the best 
discrimination between major immune cell populations and the highest fluorescence 
intensity values with a minimal cell loss compared to other erythrocyte lysing solutions87. BD 
FACS lysis solution was also certified as an in-vitro diagnostic (IVD) product which is often 
ensured with a high level of safety and efficacy. Similarly, Transfix – another IVD reagent, was 
expected to have a high performance for cryo-preservation, so in some analyses, we used it 
as a second control of fixed samples, which resembles whole blood stabilisers more than the 
unpreserved control. 
Whole blood stabilisers under investigation were Cytodelics, Proteomic stabiliser 
(PROT-1), Stable lyse stable store V2 (SSLS-V2) and Transfix. All stabilisers changed forward 
scatter/side scatter (FSC/SSC) compared to the fresh control within an acceptable range, and 
each stabiliser’s FSC/SSC profile was slightly different from each other (data not shown). This 
issue was expected since fixation with formaldehyde and low temperature were shown to 
alter cell morphology25. Compared to the fresh sample, eosinophils in cryopreserved samples 
showed the most apparent change in size, indicated by a shift to the right on the FSC axis 
(Figure 6).  
However, by adjusting acquisition voltages of FSC and SSC, it was possible to 
distinguish distinct populations of lymphocytes, monocytes, and granulocytes in all stabilisers 
except SLSS-V2 (Figure 6). Nevertheless, the overlap between monocytes and neutrophils in 
SLSS-V2 could possibly be corrected to some extent by using specific markers such as CD14 
and CD15, respectively (Figure 8). 
Some markers in samples preserved in Cytodelics were sensitive to antibody staining. 
For example, it was challenging to separate positive and negative populations using anti-
human CD16 antibody with LNK16 clone alone (Figure 6B & C). 2.5ug FcR blocking reagent 
and 100U/ml heparin were used to reduce unspecific staining. Though FcR blocker alone did 
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not show any effect, its combination with heparin was more effective to distinguish between 
different populations. However, antibody clone was more crucial to the staining quality. Both 
histogram and the FCS plot of CD16 staining with the 3G8 clone showed a more apparent 
separation between negative and positive events than the LNK16 clone. It was sufficient to 
distinguish the two populations even without FcR blocker or heparin (Figure 6B & C). It was, 
therefore, essential to test and verify antibody clones before staining for samples stabilised 
in Cytodelics. From our experience, the other stabilisers did not show such a strict preference 
for antibody clones as Cytodelics. 
It was equally important to do the antibody staining right after thawing of samples 
cryopreserved in Cytodelics. For example, after 24 hours, the fluorescence intensity of both 
CD4 and CD8 reduced. Positive and negative populations became overlapping (Figure 6D). 
Processing right after thawing was also reported to be essential for PROT-1 since blood 
samples could form clumps and change color otherwise 88.  
4.2. Detection of lineage subsets 
Samples treated with BD Facs lysing had major leukocyte lineages easily identified, as 
shown in the gating strategy in Figure 7A. As a common leukocyte marker, total CD45 
expression was used as an indicator of total leukocytes.  The other stabilisers displayed a 
similar pattern across all four donors. Median fluorescence intensity (MFI) of some lineage 
markers such as CD3, CD19, CD56, and CD14 seemed to be comparable between long-term 
cryo-preserved reagents – Cytodelics, PROT-1, and SLSS-V2. However, these MFI values were 
quite different in samples treated with BD Facs Lysing and Transfix.  For example, these two 
had CD19 signals almost twice as intense as the level of samples cryopreserved in the other 
stabilisers. The reverse trend applied for CD56 MFI (Figure 8A). Therefore, it was impossible 
to make a fair comparison between all the conditions based on non-normalised MFI values. 
Our flow cytometry panel allowed the discrimination of major CD45+ immune subsets. 
The frequency of CD15+ granulocytes was comparable between controls and preserved 
samples, whereas the distribution of monocyte subsets could not be correctly identified due 
to the signal reduction in CD14. Though experiencing a partial loss of signal, Cytodelics and 
PROT-1 treated samples had CD14 negative and positive events separately clearly. The 
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separation was almost completely abolished in SLSS-V2 and Transfix fixed samples. (Figure 
7B) 
Loss of CD14 signal resulted in a significant decrease in the frequency of classical 
(CD14+CD16–) and intermediate (CD14+CD16+) monocytes in all preserved samples (Figure 
8C). Among all stabilisers, Cytodelics had the best performance, detecting 80% of classical 
monocytes on average, whereas SLSS-V2 showed the worst outcome. One reason could be 
the overlapping between monocyte and neutrophil on SSC/FSC plots of SLSS-V2 samples, 
making the initial gating to separate them inaccurate (Figure 6A and Figure 7A).On the other 
hand, non-classical monocytes (CD14–CD16+) increased slightly in all preserved samples. 
Cytodelics, however, kept that increase modest and comparable to Transfix, the IVD product. 
(Figure 8C) 
 
Figure 7: Detection of major lineage subsets. (A) Representative flow cytometry plots of the gating 
strategy. (B) Representative histogram of CD14 expression (n=4). Non-CM, non-classical monocytes; I, 
intermediate monocyte;  CM, classical monocyte. 
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All stabilisers preserved lymphocytes reliably. Our focus was dim (CD56+CD16+) and 
bright (CD56++CD16low/–) NK cells, T cells (CD3+CD4+ or CD3+CD8+) and B cells (CD19+). The 
frequency of all these subsets was detected in both unpreserved and preserved samples 
without statistical differences. Though existing, the differences were minor, accounting for 
less than 10%). In general, Cytodelics and PROT-1 were the most robust in detecting highly 
expressed immune lineages, particularly for lymphocytes. (Figure 8D-F) 
 
Figure 8: Distribution of lineage subsets depending on types of markers and stabilisers. (A-F) 
Percentage of each lineage subsets within total CD45+ single cells, (A) granulocytes; (B) Monocytes; 
(C) T cells; (D) B cells; (F) Natural killer (NK) cells. All graphs showed median values with interquartile 
range (n=4).  Black circle – BD FACS Lysing; grey square – Cytodelics; green triangle – PROT-1, purple 
octahedron – SLSS-V2; blue hexagon – transfix. Statistical analysis was done with the Friedman test 
for nonparametric data. *,p ≤0.05;  **,p ≤0.01;  ***,p ≤0.001.  
 
4.3. Detection of T cell subsets 
As the frequency of major T cells markers – CD3, CD4, and CD8, were quite similar 
between the stabilisers and controls (Figure 8D), we investigated further how these reagents 
preserve different subsets of T lymphocytes. Here we optimised the staining for surface 
markers to distinguish between gamma delta (TCRγδ+); naïve (CCR7+CD45+), effector memory 
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(CCR7–CD45–), central memory (CCR7+CD45–), TEMRA (CCR7–CD45+) and recent thymic 
emigrant (RTE) (CCR7+CD45+CD31+CD95–) T cells. 
Both the fresh control (treated with BD FACS lysing) and commonly used cell fraction, 
peripheral blood mononuclear cells (PBMCs) exhibited comparable frequency of TCRγδ+, 
naïve, and memory T cells (Figure 9C and Figure 10A & B). Since the nature of the fresh control 
and PBMC was very different – whole blood with formaldehyde fixation and a fraction of 
blood with cryopreservation, it was expected to have a slight variation. In other words, the 
fresh control was reliable to study circulating T cell subgroups. 
The frequency of γδ T cells was variable between the fresh and cryo-preserved 
samples. There was also a two-fold reduction of this population in Transfix treated samples 
compared to the fresh control. The decline was even more severe in Cytodelics, PROT-1, and 
SLSS-V2, where the observed change was almost 3-fold (Figure 9C). This was due to the loss 
of TCRγδ signal resolution in these stabilisers (Figure 9B). Interesting, the detection was quite 
similar between these stabilisers, as observed in all four donors. This finding suggests that 
cryopreservation at a very low temperature (-80oC) may interfere with the structure of TCRγδ. 
In general, it was not optimal to assess γδ T cell frequency in whole blood after 
cryopreservation.  
Table 4: Markers to identify different circulating subpopulations of CD4 and CD8 T cells 
 
CD45RA CCR7 CD31 
Naïve  + + +/– 
Central Memory – + NA 
Effector memory – – NA 
TEMRA + – NA 
Recent thymic emigrants + + + (*) 
NA: not available or non-relevant. 
*: only for CD4 T cells 
Naïve and memory subsets of both CD4 and CD8 were detected based on expression 
of CD45RA and CCR7 (Table 4). Contrary to the expectation for an IVD graded reagent, Transfix 
maintained CCR7 signal poorly, as did also all other whole blood stabilisers. Transfix, 
Cytodelics, and PROT-1 treated samples showed far less positive CCR7 events than the 
unpreserved control. Though positive and negative population was distinguishable in CD8 
fraction, the separation was absent in CD4 fractions (Figure 10C). The reduced signal intensity 
of CCR7 explained a loss of about 40 to 50% in CD4+ naïve and central memory cells as well as 
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an increase in CD4+ effector memory population among samples treated with these three 
reagents (Figure 10A). The frequency of CD4+ RTEs was also widely different across all 
stabilisers since they were a subgroup of naïve cells.  
 
Figure 9: Cytodelics, PROT-1 and SLSS-V2 caused a reduction in the frequency of TCRγδ T cells. (A) 
Representative flow cytometry plots of the gating strategy for different T cell subsets. CM – central 
memory; EM – effector memory; EMRA – Terminally differentiated effector memory; RTE – Recent 
thymic emigrants. (B) Representative flow cytometry plots of TCRγδ expression (C) Frequency of γδ T-
cells out of total CD3+ cells across stabilisers and PBMC. Black circle – BD FACS Lysing; grey square – 
Cytodelics; green triangle – PROT-1, purple octahedron – SLSS-V2; blue hexagon – Transfix; orange 
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Figure 10: Detection of naïve and memory T cell subsets shifted significantly in Cytodelics, PROT-1 
and SLSS-V2. (A) & (B) frequency of naïve and memory T cells out of total CD3+ cells across different 
stabilisers. (C)& (D) representative histogram plots of CCR7 expression on CD4 and CD8 T cells (n=4). 
CM – central memory; EM – effector memory; EMRA – Terminally differentiated effector memory; 
RTE – Recent thymic emigrants. Black circle – BD FACS Lysing; grey square – Cytodelics; green triangle 
– PROT-1, purple octahedron – SLSS-V2; blue hexagon – Transfix; orange star – PBMC. Statistical 
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Since the CCR7 signal was better among CD8+ cells, the frequency of CD8 subsets was 
more comparable between the fresh control and samples stabilised in Cytodelics and PROT-
1. Notably, the quantification of naïve, EMRA, CM and EM subsets in Cytodelics and RPOT-1 
were comparable to the control and PBMC. Besides, Transfix performed well in detecting 
naïve T cells but poorly for EM and EMRA subsets.  In addition, SLSS-V2 was the least reliable 
reagent for phenotyping T cell subsets as there were no clear CCR7 positive events in both 
CD4 and CD8 fractions. In other words, all whole blood preserving reagents studied here 
maintained chemokine receptor – CCR7 staining intensity poorly.  
 
4.4. Detection of granulocyte activation markers  
One of the most significant advantages of whole blood cryopreservation and fixation is 
that cellular structure and integrity could be preserved right after blood drawing, reducing 
variation introduced by logistics and sample processing. If the method works, it will be ideal 
for studying granulocytes since they are short-lived and easily activated cells. In this study, 
we stimulated whole blood samples with LPS and fMLP for one hour at +37oC and then 
accessed granulocyte markers and their changes in expression in both pre-and post-
cryopreservation. 
LPS and fMLP stimulation resulted in a significant shift in the expression level of 
granulocyte activation markers in fresh controls (Figure 11B). Upon stimulation, both 
eosinophils and neutrophils were observed to have down-regulation of CD62L and up-
regulation of CD11b, CD16, and CD66b (Figure 11C). Specifically, neutrophils had CD62L MFI 
reduced by 65% on average, whereas CD11b and CD66b expression increased by more than 
100% compared to the control. On the other hand, CD16 had a modest change, only by a 20-
30% increase. Compared to fMLP, LPS stimulated the expression CD62L and CD11b more 
(Figure 11D). Although a starting volume of blood was the same between conditions, a 
significant reduction in cell count after the stimulation was observed in fMLP-treated samples 
(Figure 11B). Many cells might have died during the incubation. Not only reducing viability, 
but fMLP also had drastically changed the size and granularity of granulocytes (data not 
shown). 
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Figure 11: N-Formylmethionyl-leucyl-phenylalanine (fMLP) and Lipopolysaccharides (LPS) activated 
granulocytes. (A) Representative flow cytometry plots of the gating strategy to identify sub-
population within granulocytes - eosinophils (CD14– CD19– CD56– CD3– CD15+ CD16– Siglec-8+) and 
neutrophils (CD14– CD19– CD56– CD3– CD15+ CD16+ Siglec-8–). (B-D) Changes in granulocyte activation 
markers of fresh control upon LPS/ fMLP stimulation (n=3). (B) Representative histograms of these 
markers in neutrophils. (C) Median fluorescence intensity (MFI) in eosinophils and neutrophils. (D) 
Percentage of change in MFI of these markers in neutrophils. Data were normalised using 
unstimulated samples. The frequency below 0 indicates the percentage of reduction. (E) CD11b 
detection in samples treated with Cytodelics using different antibody clones (ICRF44, D12, and 
M1/70).  Blue area indicated CD15+ CD66b+ granulocyte population where CD11b was often found to 
be co-localised.   
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Figure 12: Granulocyte activation status were maintained but signal intensity of indicated markers 
varied across the stabilisers. Data was shown in Median fluorescence intensity (MFI) and percentage 
of change in MFI for CD62L (A), CD11b (B), CD66b (C), CD16(D). (Median with range, n=3). The 
frequency below 0 indicates the percentage of reduction. Black circle - BD FACS Lysing; grey square - 
Cytodelics; green triangle - PROT-1, purple octahedron - SLSS-V2; blue hexagon – Transfix. 
 
All whole blood stabilisers preserved the cellular activation immunophenotype after 
stimulation with  fMLP and LPS to some extent, even though activation markers were 
detected at much lower MFI than the fresh control one. Among them, PROT-1 stood out the 
most in terms of performance. It allowed the best detection of the expressional trend of 
activation markers such as CD62L, CD11b, and CD16 upon the activation with both fMLP and 
LPS (Figure 12). Though there was almost no change in CD66b expression upon fMLP 
stimulation in these samples, it was clearly elevated in LPS-stimulated ones. However, PROT-
1 could not reflect all the degree of changes in CD66b expression since we could detect only 
about a 50 percent increase in CD66b in PROT-1-treated cells compared to more than 150 
percent in the fresh controls. Similarly, all stabilisers caused a dramatic reduction in CD62 MFI 
and its proportion of MFI changes upon stimulation. Only PROT-1 retained the degree of 
CD62L decline after LPS stimulation comparable to the controls. (Figure 12). 
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The second-best performance was with Cytodelics, which preserved relatively well the 
expression of CD66b, CD16 in both fMLP and LPS treated samples and to some extent CD62L 
as well, but only after LPS treatment. Again, the MFI and percentage of MFI changes in CD62L 
and CD66b after both stimulations were much lower than in the control.  Strikingly, CD11b 
signal was almost absent due to the antibody clone used, even though we used the ICRF44  
clone that the manufacturer had validated. However, when using this clone, positive events 
were indistinguishable from negative ones (Figure 11E). The problem was mitigated by using 
D12 or M1-70 clones.  Therefore, Cytodelics seems to sufficiently maintain cellular structures 
of the markers mentioned above to detect neutrophil activation markers.  
Contrary to our expectations, Transfix performed poorly for half the markers studied 
here, CD62L and CD16. Measurement of CD11b and CD66b were similar to samples preserved 
in Cytodelics and PROT-1. On the other hand, SLSS-V2 produced the worst result that three 
out of four activation markers, CD11b, CD66b, and CD16, had either no change at all or even 
a reverse trend compared to the control (Figure 12B-D). 
 
4.5. Immune profiling of COVID-19 patients  
4.5.1. Unsupervised analysis of flow cytometry data 
 Next, we investigated whether COVID-19 patient samples cryopreserved in Cytodelics 
would be suitable for immunophenotyping by flow cytometry. Cytodelics was selected 
because it was good at preserving common immune lineages and neutrophil activation 
markers. In addition, Cytodelics also offered logistic advantages. Since it was developed and 
currently used for mass cytometry in Sweden, it allowed more collaboration between Sweden 
and our research consortium located in Finland.  
 To investigate immune signatures of SARS-COV-2 infection, we compared acute and 
convalescent phases of 14 COVID-19 patients. Aggregated flow cytometry data were 
clustered by Self-Organising Maps (FlowSOM) and visualised on Uniform Manifold 
Approximation and Projection (UMAP) (Figure 13). FlowSOM identified 13 meta clusters, 
which overlaid with UMAP map (Figure 13A&C). Based on the FlowSOM heatmap, cluster 12 
was solely CD3+ T cells, whereas Cluster 0 and 4 included CD14+ monocytes. On the other 
hand, Clusters 1, 2, 3, 5, and 7 contain different subsets of CD15+ neutrophils. These subsets 
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showed a clear differential expression of CD16, which is in line with neutrophil maturation 
states. Cluster 1 was completely negative for CD16, indicating the presence of immature cells. 
Clusters 2, 5, and 7 probably contain both immature (CD33+ CD16+) and mature neutrophils 
(CD33–/+ CD16+/++). The most interesting population was cluster 3, which was defined as 
CD16++ ARG1+ LOX-1+ Ki-67+. This cluster 3 probably contained suppressive neutrophils 
because ARG1 and LOX-1  are known to be up-regulated in suppressive neutrophils37,89,90. 
(Figure 13B and Figure 14A)  
 
Figure 13: UMAP visualisation and FlowSOM clustering of concatenated flow cytometry data. Ten 
thousand cells were subsetted from each individual in a cohort of 28 COVID-19 patients. (A) UMAP 
visualisation of all individuals pooled with FlowSOM meta cluster overlaid. Colour and number indicate 
FlowSOM cluster-ID. (B) Heatmap of the FlowSOM meta clusters showing relative expression of 
indicated immune parameters. (C) UMAP projection of expression of the indicated proteins.  
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Figure 14: Cytodelics allowed reliable detection of highly expressed immune markers in COVID-19. 
A) UMAP projection of aggregated flow cytometry data all participants with FlowSOM meta cluster 
overlaid. (B) (C) (D) Percentages of CD3+ T cells, CD15+ Neutrophils and CD14+ Monocytes, 
respectively, among total cells. Statistical analysis was done with the Wilcoxon matched-pairs signed-
rank test for nonparametric data. *,p ≤0.05;  **,p ≤0.01;  ***,p ≤0.001. 
 
4.5.2. Longitudinal analysis of immune cell subsets in COVID-19 
 Next, we looked at the percentage of major lineage markers in each participant. The 
frequency of CD3+ T cells decreased significantly in the acute compared to the convalescent 
samples, reflecting lymphopenia often seen in acute COVID-19. The T cell number increased 
almost two-fold after 90 days from symptoms onset. In addition, a similar reduction was 
observed in the frequency of CD14+ monocytes, whereas the frequency of CD15+ neutrophils 
elevated significantly during the acute phase.  
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4.5.3. Detection of neutrophil subsets in COVID-19 patients 
 As mentioned above, different subsets of neutrophils were identified by FlowSOM 
clustering, showing a separation of immature, mature, and activated cells based on CD16 
expression (Figure 15A). Cluster 1 was entirely negative for CD16, indicating the presence of 
immature cells. These CD16– immature neutrophils increased significantly during the acute 
phase of the SARS-COV-2 infection. Acute samples of both the hospitalised and ICU groups 
displayed a similar elevation of CD16– without statistical differences. (Figure 15B) 
 According to FlowSOM, clusters 3, 2, 5, and 7 encompassed both immature (CD33+ 
CD16+) and mature neutrophils (CD33–/+ CD16+/++). Unfortunately, no statistical difference 
was detected between the acute and convalescent samples regarding these immature and 
mature neutrophil subsets. Moreover, there was no statistical difference between the acute 
and convalescent samples when the hospitalised and ICU groups were analysed separately . 
(Figure 15C – E) 
 Within the CD16high population, cluster 3 had a similar phenotype to suppressive 
neutrophils based on their expression of CD16, ARG1 and LOX-1. ARG1 and LOX-1 have been 
shown to be up-regulated in suppressive neutrophils37,89,90. However, we found no difference 
in frequency of these cluster 3 cells between acute and convalescent samples in either the 
hospitalised or ICU cohort. Surprisingly, this population accounted for 20 percent of total 
studied cells on average, which might indicate that other non-suppressive neutrophils can 
express LOX-1 and ARG1. Moreover, some patients had a very high number of these 
suppressive cells, up to 40% of total studied cells, whereas some patients had less than 5%. 
The phenomenon of dramatic differences in cluster 3 population between individuals was 
observed in both hospitalised and ICU cohorts.  In addition, these suppressive-like cells were 
highly proliferative due to a high expression of Ki-67 compared to other subsets. In 
conclusion, we were unable to confirm if cluster 3 represented solely suppressive neutrophils 
or if it also contained other mature and activated neutrophils. (Figure 15E) 
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Figure 15: Variation in the detection of neutrophil sub-population. (A) UMAP projection of different 
subgroups among hospitalised and ICU COVID-19 samples with FlowSOM metaclusters overlaid. (B)-
(E) Percentage of neutrophil subpopulations of total cells according to FlowSOM metaclusters, CD16– 
(B); CD16+ (C); CD16++ (D); CD16++ ARG1+ (E). Statistical analysis was done with the Wilcoxon matched-
pair signed rank test for nonparametric data. *,p ≤0.05;  **,p ≤0.01;  ***,p ≤0.001. 
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5. Discussion 
This study used flow cytometry to investigate the performance of four commercial 
whole blood cryopreserving stabilisers on maintaining leukocyte surface markers. Our main 
finding was that the detectability of well-defined and highly expressed immune cell lineages 
was reasonably accurate in preserved samples. Nevertheless, depending on targeted 
markers, fluorescence intensity varied between different stabilisers as well as between 
stabilisers and fresh controls. There was no single best stabiliser that worked for all cell types. 
Different cell types, markers, antibody clones, processing time and techniques decided the 
best suitable stabilisers.  
 
5.1. Immunophenotyping of cryopreserved whole blood.  
Whole blood freezing offers an alternative to the standard procedure – PBMC isolation 
and cryopreservation with cryo-protectants. Though widely used, the multi-step and time-
consuming process of PBMC preparation could alter cellular characteristics91. Additionally, it 
eliminates high-density cells such as granulocytes, which represents 70% of total leukocytes. 
Whereas,  whole blood cryopreservation offers 1) a rapid process that minimizes changes in 
cellular structures after the removal of physiological environments; 2) a simple and 
inexpensive procedure that requires a smaller sample volume than PBMCs and allows a 
collection of many samples simultaneously without highly trained staff and complex 
equipment; 3) cell fixation making the method safe for highly infectious samples such as 
COVID-19 or Ebola; 4) a good representation of whole blood composition by retaining 
granulocyte populations.  
To date, our study is the first comprehensive analysis of multiple whole blood 
cryopreserving reagents for flow cytometry. Using cryopreserved samples is a common 
practice, but most studies used PBMC fraction only and focused on immune subsets' viability 
and functional capacity, particularly lymphocytes post cryopreservation. Since the whole 
blood cryopreservation is efficient and straightforward, multiple efforts have been made to 
test its validity in multicenter or field immunophenotyping studies. However, these studies 
mainly focused on major immune lineages or specific markers with one to two whole blood 
stabilising reagents. Some notable studies include 1) comparison between Phosphoflow Fix 
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and Lyse, and PROT-1 for profiling lineage markers in flow cytometry and mass cytometry by 
Rybakowska P. et al.83; 2) cryopreservation method to study granulocyte activation developed 
by Ruiter K.D et al.25; (3) mass cytometry analysis of whole blood stabilisers on chemokine 
receptors by Sakkestad ST et al.92. This study sought to expand on their work, investigating 
the performance of stabilising reagents - Cytodelics, PROT-1, SLSS-V2, and Transfix for flow 
cytometry analysis of neutrophils and their activation markers, monocytes, B cells, NK cells 
and T cell subpopulations. The workflow adhered to manufacturers’ recommendation, and all 
the staining were done using antibody cocktails to minimize staining variability between 
samples.     
 
5.2. Antibody staining after fixation  
Staining post-fixation and cryopreservation might cause high background staining.  As 
samples were fixed and cryo-preserved right after the collection, it was impossible to exclude 
dead cells before the staining. Dead cells could take up antibodies non-specifically and have 
a high autofluorescence, subsequently interfering with data interpretation. Nevertheless, the 
amount of cell death was probably small since the interval between the blood drawing and 
sample processing was reasonably short. Moreover, the fixation process for all stabilisers had 
a minimal procedure of one to two times pipetting and a short incubation at RT.  
Staining post-fixation was challenging due to a loss of signal or false positives. Fixation 
and permeabilization could alter antigen structures or generate unspecific binding sites93. All 
stabilisers here use formaldehyde as a primary fixative, which makes non-selective crosslinks 
between proteins. These crosslinks might lead to changes in three-dimensional 
conformations of target proteins, thus reducing their immunoreactivity with antibodies. 
While over-fixation could cause excessive cross-linking, under-fixation could result in unequal 
crosslinks between the cell surface and intracellular locations, making them more susceptible 
to cryo-damages.94 
Moreover, all the studied antibodies here were monoclonal, each of which bound to 
only one epitope on target antigens. If the cross-linking by fixatives impaired that structure, 
it would generate false-negative events. This explained why the markers in this study, such as 
CD16 and CD11b (Figure 6 and Figure 11) were sensitive to antibody clones since each clone 
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recognises only one epitope. From our experience, PROT-1 seemed to preserve antigen 
structures more robustly than Cytodelics since the latter only worked for a much smaller 
selection of antibody clones, or otherwise it would result in a reduction or even a complete 
loss of MFI signal. Thus, fixation time, antibody clones and titration need to be considered 
carefully during panel optimisation. 
 
5.3. Antigenic detection after fixation and cryopreservation 
5.3.1. Effects of fix/freeze/stain workflow 
The workflow of all studied whole blood stabilisers followed a fix/freeze/stain 
procedure. The process could introduce several technical biases, such as 
fixing/freezing/thawing time and temperature. The detection of antigens was also dependent 
on individual marker sensitivity to fixation and cryopreservation as mentioned above. Our 
results showed that highly expressed markers endured the fixing and freezing process better 
than low-expressed antigens, which was in agreement with previous studies83,95. This might 
be owing to both their abundance and more stable nature.  
In addition, fixing and freezing altered cell morphologies as indicated in FSC and SSC 
profiles compared to fresh control. The most affected cells were monocytes and granulocytes, 
which are in agreement with previous studies25,83,96. Despite that, Cytodelics, PROT-1 and 
Transfix offered clear segregation of granulocytes, monocytes and lymphocytes comparable 
to the fresh control.  
 
5.3.2. Robust preservation of major lymphocyte subsets 
Our result demonstrated that cryopreserving reagents – Cytodelics, PROT-1, and 
Transfix reduced fluorescence intensity but maintained similar percentages of major 
lymphocyte subsets to those obtained with the standard stain/fix/lyse procedure of BD Facs 
Lysing solution (Figure 8). T, B and NK cells were correctly detected across all the stabilisers.  
These results are in line with a previous study done by Pinto et al. that the freezing of fixed 
whole blood made no dramatic alteration to the frequency of lymphocyte subsets despite a 
reduction in signal intensity95. There was a slight decrease in CD16 signal, but the detection 
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of NK cell subsets based on CD16 was comparable to the controls. The trend was in contrast 
with the previous finding that a reduced CD16 signal hindered the determination of monocyte 
subsets83. This might be due to different antibody clones and sample processing methods. 
  
5.3.3. Hampered separation of T cell sub-population 
Here we reported how the four whole blood cryopreservation kits performed for γδ T 
cells and sub-population of CD4 and CD8 T cells.  For γδ T cells, better results were obtained 
in Transfix, and the data more closely resembled PBMC than the fresh control. On the other 
hand, Cytodelics, PROT-1 and SLSS-V2 caused a significant reduction in TCR-γδ signal, making 
it impossible to distinguish between negative and positive events. The fixatives in these 
reagents might have destroyed binding sites for the antibody. One solution is to replace our 
current B1 clone with gamma3.20 or H-41 for TCR γδ. These clones were extensively studied 
and confirmed to work with Formalin-Fixed Paraffin-Embedded Tissues, indicating that it 
might work with formaldehyde fixation found in all the stabilisers97. Unfortunately, we have 
found no directly fluorochrome-conjugated antibody for flow cytometry having either of 
these clones. However, it might be possible to stain cells with a primary antibody bearing 
these clones, followed by a fluorochrome-conjugated secondary antibody.   
The determination of α/β CD4 and CD8 T cell subsets was challenging owing to the 
lower CCR7 signal. Here we were unable to identify correctly naïve, recent thymic emigrants, 
central memory, effector memory and terminally differentiated effector memory cells using 
these four stabilisers. Formaldehyde fixation and cryopreservation had detrimental effects on 
CCR7 signal resolution as shown in Figure 10. The attenuation of CCR7 signal was reported 
before, but mainly on mass cytometry data92,98.  
The CCR7 signal separation was entirely lost on CD4 population, making it impossible 
to distinguish between naïve and memory subsets. However, the situation was improved with 
CD8 where Cytodelics and PROT-1 maintained the frequency of T cell subsets comparable to 
the controls. It was not clear why CCR7 on CD4 and CD8 behaved differently. One possible 
explanation was due to the abundance of CCR7 on each subset. Despite that, the distribution 
of CD4 subsets deviated far from acceptable ranges. Thus, CCR7 or most likely also other 
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chemokine receptors, in general, are not suitable for fix/freeze/stain procedure, specifically 
for these whole blood stabilisers92. 
 
5.3.4. Unreliable detection of monocyte composition 
  When testing deeper immunophenotyping of innate cell populations,  we could not 
distinguish monocyte subsets reliably in all cryopreserved samples due to the partial loss of 
CD14 signal intensity. Cytodelics showed to be the most suitable stabilisers for classical 
monocytes, followed by PROT-1 and Transfix.  One approach to improve the signal intensity 
could be to use a brighter fluorochrome than PerCP-Cy5.5. Although our current clone was 
validated by Cytodelics’ manufacturer, switching antibody clones and increasing antibody 
titration might also help.  
SLSS-V2 was problematic for monocytes. Not only having a reduced signal intensity, 
SLSS-V2 also caused a significant shift in cell morphologies, as indicated by the shift in FSC/SSC 
profiles. Changing PMT voltages of FSC and SSC yielded no improvement for the separation 
of monocytes and granulocytes. The issue might be due to harsh fixation and lysis in SLSS-V2 
during the freezing process. It might also be a trade-off for a more straightforward thawing 
process – SLSS-V2 protocol only required two washing steps while preserving samples at more 
versatile temperatures than other stabilisers.   
 
5.3.5. Perpetuation of neutrophil activation status  
Our study showed that Cytodelics, PROT-1 and, Transfix maintained the activation 
status of neutrophils after fMLP and LPS stimulation. The elevation of CD66b, CD11b and 
CD16 and reduction of CD62L were clearly observed in samples treated with these stabilisers, 
with one exception of CD11b in Cytodelics, which required another antibody clone for reliable 
detection. However, the proportion of change in CD11b, CD16, and CD62L was comparable 
to the controls only in PROT-1 preserved samples stimulated with LPS. Cytodelics allowed a 
correct quantification of changes in CD16 and to a lesser extend in CD11b when a correct 
antibody clone was used (data not shown). In addition, CD66b signal was weak in all stabilisers 
compared to the controls, indicating that CD66b was not suitable for studying in fixed and 
frozen samples, which is in agreement with the previous report25. In addition to that, all tested 
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activation markers were poorly detected in SLSS-V2 and to some extent in Transfix. Therefore, 
PROT-1 and Cytodelics would be more suitable for preserving neutrophils’ activation status.  
PROT-1 and Cytodelics conserved neutrophil activation status regardless of 
differences in MFI and proportion of MFI changes compared with the unfixed control. The 
finding is in line with a previous study done by Ruiteet et al., where they examined neutrophil 
activation markers following fix/freeze/stain procedure25. Our study contributed further to 
the field with an understanding of how effective four commercial cryopreservation kits are 
for granulocytes and how much the proportion of MFI changes in the aforementioned 
activation markers deviated in fixed and cryopreserved samples.  This discrepancy indicates 
that PROT-1 and Cytodelics did not fully capture the scale of activation and cellular changes 
in neutrophils.   
While the controls showed a similar cellular change between fMLP and LPS 
stimulation, the fixed and cryopreserved samples demonstrated that LPS activated 
neutrophils more than fLMP (Figure 12). The difference could be due to a massive amount of 
cell death after fMLP treatment (data not shown). The 1-hour treatment of fLMP might have 
been harsh on cells, reduced viability and possibly altered antigenic structures. In our 
preliminary study, 5-minute stimulation with fMLP was sufficient to activate neutrophils. 1-
hour time point was used to simplify the experimental workflow. 
 
5.4. Whole blood cryopreservation for flow cytometry and mass cytometry 
 Mass Cytometry or Cytometry by Time-Of-Flight (CyTOF) and flow cytometry (FC) are 
widely used for immunophenotyping. They both detect numerous parameters at a single-cell 
level. However, whole blood cryopreservation by Cytodelics, PROT-1, and SLSS-V2 are more 
widely used in CyTOF than in FC. The limitations of fluorochrome technology make antigenic 
detection in fixed and frozen samples more challenging. First, FC is less sensitive and prone 
to error due to spillover and autofluorescence. Correction for spectral overlap requires 
compensation, which could introduce variation to data interpretation. High-dimension FC 
panels increase the complexity of compensation matrix, making it more prone to the loss of 
signal resolution. Second, FC can also take cell-associated autofluorescence into analysis. 
Thus, fluorescence spillover and autofluorescence background are detrimental to detecting 
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low abundance antigens, particularly when their sensitivity to antibody staining has been 
reduced by fixation and cryopreservation.99,100  
 On the other hand, CyTOF has higher sensitivity while requiring little or no 
compensation. CyTOF has a low background since it uses a time-of-flight mass spectrometer 
to analyse element isotopes that label antibodies instead of fluorochromes. A minimal 
background with no spectral spillover and correction in CyTOF allows excellent discrimination 
of negative and positive populations even with low signal intensity.101  
 These differences in underlying technologies of FC and CyTOF might explain the 
discrepancy in the detection of certain antigens. For example, we were unable to reliably 
identify CD62L and CD14 signals in Cytodelics-fixed samples, contrary to our previous study 
where detection was done using CyTOF102.  However, the loss of signal was often observed in 
the FC detection of markers expressed at low levels, whereas highly expressed markers were 
impacted less.  Thus, Cytodelics or PROT-1 can be used for FC with consideration of cellular 
or antigenic targets and thorough testing.  
 
5.5. Application in COVID-19 
5.5.1. Reliable detection of major immune subsets from cryopreserved prospective 
samples from COVID-19 patients 
Analysis of 14 patients with longitudinal samples preserved in Cytodelics revealed the 
striking differences in T cells, monocytes, and neutrophils between acute and convalescent 
phases. Hospitalised and ICU patients had an abnormally low number of CD3 T cells during 
the acute infection, indicating lymphopenia often found in severe cases103. In addition, the 
reduction of CD14+ monocyte, mainly classical monocytes, during the early SARS-COV-2 
infection in severe patients was similar to a previous finding104. Cytodelics also allowed 
detection of emergency granulopoiesis during the acute phase, as indicated by an increase in 
both total CD15+ neutrophils and their immature compartment. These findings are in 
agreement with the current understanding of immune responses in COVID-19104–106. 
Identifying these differences further confirms that Cytodelics preserved highly expressed 
lineage markers sufficiently for immunophenotyping by flow cytometry.  
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5.5.2. Inadequate detection of temporal changes in neutrophil sub-population   
FlowSOM clustering identified different subsets of neutrophils in Cytodelics-preserved 
patient samples. The unsupervised analysis confirmed the heterogeneity of neutrophil 
populations during the SARS-COV-2 infection. Our result showed that early progression of 
COVID-19 was marked with the expansion of CD16– immature neutrophils, which was also 
reported previously by Reusch et al.75. However, our flow cytometry panel could not identify 
some apoptotic and non-functional neutrophils which might be included in CD16– immature 
neutrophils107.   
On the other hand, no significant difference was observed for other neutrophil subsets 
between the acute and convalescent phases of either hospitalised or ICU patients. 
Particularly, a similar trend was found for suppressive neutrophils which was identified as Lin– 
CD15+ CD11b+ CD33low/+ HLA-DR–/low LOX-1+ ARG1+ PD-L1+ in FlowSOM cluster 3 (Figure 15E). 
Moreover, no dramatic difference was detected even if FlowSOM clustering was iterated with 
a higher number of clusters (data not shown). The finding did not resemble current literature 
on the expansion of this suppressive neutrophil population during the early phase of SARS-
COV-2 infection108,109. Our relatively small patient cohort might have been insufficient to 
detect a statistical significance, although some studied subjects displayed strikingly high levels 
of these suppressive cells. On the other hand, 21 to 90 days might not have been enough for 
suppressive neutrophils to return to their normal level since Sieminska et al. reported that 
mild and asymptomatic COVID-19 had MDSCs persisting in convalescence, even three months 
after the infection110.  However, further study is needed to understand why some studied 
subjects had these suppressive neutrophils increased significantly (Figure 15E). 
Identifying suppressive neutrophils in whole blood samples is challenging due to 
biological heterogeneity of neutrophils and technical limitations. Both immature MDSC and 
mature populations can display suppressive functions37. There is currently no consensus on 
how to identify suppressive neutrophils or MDSC from whole blood. While Apodaca et al. 
suggested that whole blood yields the most accurate results111, others have argued that G-
MDSC should only be analysed from PBMC fractions33,112. Moreover, our results show LOX-1 
is expressed at different levels across neutrophil subsets instead of only in suppressive 
population as has been suggested before89. In addition, ARG1 has been reported to be 
released by normal neutrophils upon activation38. In other words, LOX-1 and ARG1 might not 
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be sufficient to differentiate suppressive neutrophils from other neutrophil populations, 
particularly in COVID-19 patients.  
On the other hand, unsupervised analysis using our current flow cytometry panel 
might be insufficient to detect suppressive populations. Signal intensity of all markers was not 
equal, making it more difficult to detect very dim signals with FlowSOM clustering and UMAP 
visualisation113. For example, extremely low signal PD-L1 appeared negative on the heatmap 
for FlowSOM metaclusters. More preprocessing steps could be used, e.g. FlowAI/FlowClean 
for cleaning data or Cytonorm for data normalisation in addition to downsampling and the 
removal of debris, singlets, and eosinophils114–116. This could help to reduce further 
background signal and normalise signal intensity for unsupervised analysis. However, there 
would be a risk of over-transformation of the data since the compensation had transformed 
it already beforehand. On the other hand, automated analysis might fail to identify a 
population that accounts for less than 5% of the total cells117. Suppressive neutrophil 
frequencies vary between individuals. Particularly in some patients, the numbers can be tiny, 
making them challenging to detect. In conclusion, it is not straightforward to identify this 
population in cryo-preserved whole blood samples. A further study with a bigger cohort and 
better data processing is needed to the issue. 
 
5.6. Conclusion and future perspectives 
All in all, the aforementioned commercial whole blood stabilising kits can be used for 
immunophenotyping in flow cytometry. There are various approaches to continue this project 
and improve the efficacy of these stabilisers.  
First, further optimisations are needed to increase the efficacy of these whole blood 
stabilisers for low abundance markers. One approach is to stain samples before adding 
stabilising buffers.  A stain/fix/freeze procedure would reduce the detrimental effects of 
formaldehyde fixation on epitope structures, thus preserving their immunoreactivity with 
antibodies.  Moreover, antibody staining before cryopreservation can incorporate dead cell 
markers to access sample viability and decrease unspecific staining.  However, the 
stain/fix/freeze workflow might risk complicating the sample collection, particularly in clinics 
where nurses or staffs have limited time and facility to do antibody staining.  
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  Next, it would be interesting to investigate how these whole blood stabilisers preserve 
intracellular markers for immune phenotyping in flow cytometry. After being thawed and 
stained for surface markers, samples can be permeabilized by detergents e.g. saponin, and 
then stained for intracellular markers. However, it is unclear if the stabilising buffers can cause 
cell permeabilization and how it could affect the staining of intracellular markers. Therefore, 
selection of compatible antibodies and experimental workflow is essential to achieve the best 
result.  
Lastly, we plan to analyse a bigger cohort of COVID-19 patients to determine if Cytodelics 
is suitable for studying granulocytes. The current patient cohort is small, with only 14 patients, 
and immune profiles are highly variable between individuals. As a result, it is inconclusive if 
our negative findings on different granulocyte subsets in COVID-19 were entirely due to 
Cytodelics and our workflow or it is because of patient-to-patient variation. Moreover, we 
plan to look deeper into the clinical data of some patients displaying a high level of 
suppressive neutrophils, as shown in Figure 15E. It might be possible to determine if there is 
any underlying clinical data differentiating them from other patients.  
In conclusion, this thesis provided an in-depth analysis on the detectability of a wide 
range of cell surface makers fixed and cryopreserved in  Cytodelics, PROT-1, SLSS-V2 and 
Transfix. Although fixation and cryopreservation altered fluorescence intensity, antibody 
affinity and cell morphology, PROT-1, Cytodelics and Transfix allow robust identification of 
major immune lineages by flow cytometry. Notably, rapid sample processing with minimal 
requirements of facility makes them a valuable tool for field studies, especially for infectious 
diseases like COVID-19.  
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